Measuring the Activated Clotting Time in patients receiving unfractionated heparin prior to coronary angiography and intervention. A single-centre validation study comparing different blood sampling sites

Withdrawn

Conditions: coronary artery disease
10011082

Registration Number: NL-OMON43038

Lead Sponsor: Medisch Centrum Alkmaar

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Withdrawn

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

Consecutive patients scheduled for diagnostic coronary angiography or elective percutaneous coronary intervention (PCI) are screened for entry into this study. Patient are eligible for this study when it is expected that the scheduled procedure will be accomplished with a single bolus of heparin, i.e. patient undergoing a procedure with expected duration of > 1 hour will not be included in this study.

Exclusion Criteria

- Use of novel oral anticoagulants or vitamin K antagonists
- Chronic use of non-steroid anti-inflammatory drugs with the exception of aspirin
- Known renal insufficiency (e.g. serum creatinine level of more than 265 *mol/L (i.e. more than 3.5 mg/L))
- Liver function disorders with coagulopathies (PT >1.5N, INR >2.0 and/or thrombocyte count < 100 x 109/L)
- Suspicion of unstable coronary artery disease with chest pain in rest, ECG changes, elevated cardiac markers, or hemodynamic instability at the time of the procedure
- Serious known concomitant disease with a life expectancy of less than one year
- Unability to read and understand the Dutch language
- Previous participation in this study

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Variability in ACT measurements at different blood sampling sites at the end of<br /><br>coronary angiography or intervention in patients receiving pre-procedural UFH.</p><br>

Secondary Outcome Measures